METHODS OF TREATMENT FOR CYSTIC FIBROSIS
This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof.The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 16. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ALTSHULER DAVID M [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-16, Last update posted on www.tib.eu: 2023-10-10, Last updated: 2023-10-13 |
|---|
| Patentnummer: |
EP4218754 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017780233 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017780233 | ||
| 003 | DE-627 | ||
| 005 | 20231013135632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230811s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017780233 | ||
| 035 | |a (EPA)EP4218754 | ||
| 035 | |a (EPA)68808572 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ALTSHULER DAVID M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METHODS OF TREATMENT FOR CYSTIC FIBROSIS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-16, Last update posted on www.tib.eu: 2023-10-10, Last updated: 2023-10-13 | ||
| 520 | |a This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof.The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ANDERSON COREY DON |4 aut | |
| 700 | 0 | |a CHEN WEICHAO GEORGE |4 aut | |
| 700 | 0 | |a CLEMENS JEREMY J |4 aut | |
| 700 | 0 | |a CLEVELAND THOMAS |4 aut | |
| 700 | 0 | |a COON TIMOTHY RICHARD |4 aut | |
| 700 | 0 | |a FRIEMAN BRYAN |4 aut | |
| 700 | 0 | |a GROOTENHUIS PETER |4 aut | |
| 700 | 0 | |a HADIDA RUAH SARA SABINA |4 aut | |
| 700 | 0 | |a HARE BRIAN J |4 aut | |
| 700 | 0 | |a KEWALRAMANI RESHMA |4 aut | |
| 700 | 0 | |a MCCARTNEY JASON |4 aut | |
| 700 | 0 | |a MILLER MARK THOMAS |4 aut | |
| 700 | 0 | |a PARASELLI PRASUNA |4 aut | |
| 700 | 0 | |a PIERRE FABRICE |4 aut | |
| 700 | 0 | |a ROBERTSON SARAH M |4 aut | |
| 700 | 0 | |a SOSNAY PATRICK R |4 aut | |
| 700 | 0 | |a SWIFT SARA E |4 aut | |
| 700 | 0 | |a ZHOU JINGLAN |4 aut | |
| 700 | 0 | |a BOREK BARTLOMIEJ |4 aut | |
| 700 | 0 | |a VAN GOOR FREDRICK |4 aut | |
| 700 | 0 | |a YOUNG TIM |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 16. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:16 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/68808572/publication/EP4218754A1?q=EP4218754 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 16 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 16 |c 08 | ||